
News|Articles|August 4, 2026
Pediatric clinical trial update: July 2026
Author(s)Morgan Ebert, Executive Editor
Fact checked by: Benjamin P. Saylor
A look back at the latest clinical trial updates for the pediatric population during July 2026.
Advertisement
Advertisement
July's clinical trial news spanned a wide range of pediatric subspecialties, from a large real-world comparison of biologics in inflammatory bowel disease to early-phase pharmacokinetic work in atopic dermatitis, exploratory biomarker findings in Fontan-associated liver disease, and dueling readouts in food allergy and ADHD therapeutics. Several reports came from ongoing trial programs building on already-approved therapies, while others offered early looks at agents still years from a regulatory decision.
Related to this article

In SURMOUNT-ADOLESCENTS, tirzepatide cut BMI 18.5% at 72 weeks vs a 0.5% rise with placebo in adolescents with obesity.

Caregivers reported itch, symptom, and QOL gains with roflumilast cream 0.05% in infants with AD; an FDA decision is due February 2027.

Novo Nordisk filed etavopivat for SCD in patients aged 12+, backed by phase 3 HIBISCUS data showing a 27% drop in vaso-occlusive crises vs placebo.

In STEP Young, semaglutide cut BMI 13.5% at 68 weeks vs a 2.7% rise with placebo in children aged 6 to <12 years with obesity.

In a matched cohort of children aged 6 and younger with EoE, dupilumab was linked to less incident asthma than swallowed budesonide (10.5% vs 16.2%).

Full OptIMMize-1 results show high skin clearance rates with risankizumab in children and teens with psoriasis, sustained through 52 weeks.

Post hoc data show cariprazine improved both manic and depressive symptoms through 52 weeks in youth aged 10 to 17 years with bipolar I disorder.
Advertisement
Advertisement

